A Virtual Reality View: New Approaches to the Diagnosis and Treatment of Pediatric and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis

 

REGISTER FOR LIVE VIRTUAL CME PROGRAM

 

Feel free to pass this invitation on to your physicians, fellows, physician assistants, nurses, pharmacists, healthcare practitioners, and any other colleagues who you believe would be interested in participating in this free educational program.

 

Thursday, May 28,2020

8:00am-9:00am CT

Please note this Virtual program is 9:00AM Eastern, 8:00AM Central, 7:00AM Mountain and 6:00AM Pacific.

PROGRAM FEATURES

    • Virtual reality animations
    • Personalized poster portal
    • Interactive, case-based learning environment

PROGRAM DESCRIPTION

While guidelines regarding the management of AD in children have been published, variability persists in practice. Treatment inconsistencies and the chronic and relapsing nature of AD can lead to frustration for patients, family, and caregivers when managing AD. This program will focus on providing AD caregivers an update on recent pathophysiological findings that drive new therapeutic targets; reviewing severity and diagnosis of AD; and discussing the clinical profiles of existing and emerging agents, with focus on treatment individualization.

FACULTY

Amy S. Paller, MD
Chair, Department of Dermatology
Director, Northwestern University Skin Disease Research Center (SDRC)
Walter J. Hamlin Professor of Dermatology
Professor of Dermatology and Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, IL

Peter A. Lio, MD
Clinical Assistant Professor
Dermatology and Pediatrics
Northwestern University Feinberg School of Medicine
Medical Dermatology Associates of Chicago
Chicago, IL

PROGRAM FEATURES

  • Virtual reality animations
  • Personalized poster portal
  • Interactive, case-based learning environment

PROGRAM DESCRIPTION

While guidelines regarding the management of AD in children have been published, variability persists in practice. Treatment inconsistencies and the chronic and relapsing nature of AD can lead to frustration for patients, family, and caregivers when managing AD. This program will focus on providing AD caregivers an update on recent pathophysiological findings that drive new therapeutic targets; reviewing severity and diagnosis of AD; and discussing the clinical profiles of existing and emerging agents, with focus on treatment individualization.

LEARNING OBJECTIVES

  • Apply updated diagnostic guidance for pediatric and adolescent patients with moderate-to-severe AD and use severity assessments to inform management decisions
  • Review the clinical profiles and mechanisms of action of newly approved and emerging systemic/biologic agents for the treatment of pediatric and adolescent patients with moderate-to-severe AD
  • Explain the benefits associated with patient centered, team-based shared decision-making approaches for the management of moderate-to-severe AD in children and adolescents

TARGET AUDIENCE

This activity is intended for US-based pediatric/adolescent dermatologists, allergists/immunologists and other health care professionals who diagnose and manage pediatric/adolescent patients with moderate-to-severe AD.

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 creditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with AD. Credits: 1.0 ANCC Contact Hours.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLAIMER

Med Learning Group makes every effort to develop activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For questions, please contact Med Learning Group at info@medlearninggroup.com.
Privacy and confidentiality policy statement information is available at www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event Staff will be glad to assist you with any special needs (i.e. physical, dietary, etc.) Please contact Med Learning Group prior to the live event at info@medlearninggroup.com

 

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.